Microchip Technology (MCHP) — 2026Q4 FY2026 Earnings Call Analysis

Sold Out Everywhere, Not Raising a Single Price

Substrates constrained, 3nm at half the world's need, lead times extending, and they have raised zero prices.

Thesis: The cycle is turning across every channel simultaneously and constraints are tightening, but this company has zero pricing power in the tightest market since COVID. They are choosing relationship repair over margin capture, meaning all gross margin improvement comes from utilization, not ASP. With 35% internal wafer capacity, no 300mm IP, and $100M capex mostly maintenance, they are structurally unable to defend or expand margins themselves. The recovery is real but the leverage sits with foundries and substrate suppliers, not MCHP.

Verdict: HOLD — Conviction: MEDIUM

Catalyst: Underutilization charges declining quarter by quarter as fabs ramp, pushing non-GAAP gross margin toward 65% organically without needing price increases. Management explicitly guided this: 'each quarter, they will be reducing.'

Key Risk: Channel restock reverses. Distributors are ordering 'in droves' to refill below-normal inventory. Once filled, orders flip negative against a company guiding inventory down from 185 days over two quarters. Classic Inventory Divergence setup.

The Tell: Sanghi corrected an analyst in real time: 'Actually, we did not say we were increasing capacity. That was not in the prepared remarks.' A CEO who is that precise about managing capacity narrative while simultaneously describing substrates as constrained, lead times as expanding, and 3nm at half world demand is telling you they will not spend to relieve the bottleneck. The constraint is the margin, and they won't fix it.

Detected Patterns

Zero Pricing Power Despite Constraints: Sanghi confirms substrates constrained, 3nm at half world need, lead times expanding, non-supported dollar volume up significantly, yet states plainly: 'as we speak right now, we have not increased our prices.' He's choosing not to capture the margin the constraint environment allows.
Inventory Divergence: Distribution inventory 'fully corrected, actually to be below normal' with restocking orders landing. Company guiding its own inventory down from 185 days over two quarters. Channel refilling while company drains die inventory. When distributors are full, orders reverse against a leaner balance sheet.
Capacity Ceiling: 35% internal wafer capacity, no 300mm IP after license fell away, $100M capex mostly maintenance, escalating for foundry allocation at senior levels. Sanghi corrected the analyst: 'we did not say we were increasing capacity.' Can grow into prior capacity but cannot add new capacity.
Say/Do Gap: Non-GAAP operating income 26.3% vs GAAP 10.4%. Non-GAAP net income $933.9M vs GAAP $118.8M. The $815M annual gap between adjusted story and filed numbers. 65% margin target reached only by adding back $46.6M of underutilization charges.
Beat Above Buy-Side Whispers: Non-GAAP EPS $0.57 beat guidance midpoint by $0.07. Distribution inventory corrected below normal simultaneously across channels. Six Gen6 design wins pre-production is unusual and management called it out unprompted.
Narrative Shift to Inference: CFO pivoted to 'agentic AI and inference-based workloads' as the growth driver, calling training the past super cycle. Classic shift when training narrative peaks. Management declined to size any data center revenue contribution.

Friction Level: MODERATE_FRICTION — Both sides agree constraints are real and the beat is genuine. The disagreement is whether the recovery is structural end-demand inflection or a channel restock that reverses when distributors refill. Sanghi's 'customers returning in droves' versus classic restock-cycle timeline.

Report not found

The report data is no longer available. Please return to the archive.

Sold Out Everywhere, Not Raising a Single Price | Silicon Signal